NCT05199584 2026-03-05A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function MutationsEndeavor Biomedicines, Inc.Phase 2 Completed20 enrolled
NCT04042753 2025-08-08Nivolumab and Ipilimumab in People With Aggressive Pituitary TumorsMemorial Sloan Kettering Cancer CenterPhase 2 Active not recruiting9 enrolled